- 日
- 関
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/01/13 20:42:28」(JST)
wiki en
English Journal
- [Multicenter prospective survey of prognosis of hypertensive elderly outpatient under antihypertensive treatment--morbidity and mortality of cardiovascular diseases and cancer].
- Ogihara T1, Morimoto S, Nakahashi T, Hiwada K, Matsuoka H, Matsumoto M, Shimamoto K, Onchi Y, Abe I, Mikami H, Ishimitsu T, Kohara K, Takizawa S, Takasaki M, Masuda A, Munehira J, Eto M, Takagawa Y, Kiyohara Y, Ibayashi S, Nakamura T, Fujishima M.Author information 1Department of Geriatric Medicine, Osaka University Medical School.AbstractAlthough calcium-channel blockers and angiotensin-I-converting enzyme inhibitors are often used for treatment of hypertension in the elderly in Japan compared to those in the United States and in European countries, there have been few investigations on the prognosis of the elderly receiving these antihypertensive treatments. The Research Group for "Guidelines on the Treatment of Hypertension in the Elderly" collaborated with the Comprehensive Research Projects on Aging and Health group of the Ministry of Health and Welfare of Japan in performing a 3-year survey on the outcome of 700 hypertensive elderly outpatients (> or = 60 years) receiving treatment of antihypertensive drugs. Antihypertensive drugs including dihydropyridine-type calcium channel blockers, beta blockers, angiotensin-I-converting enzyme inhibitors, diltiazem, diuretics and old-type antihypertensives (hydralazine, budralazine, and centrally acting drugs such as clonidine, methyldopa and guanabenz) were administered to 71.3%, 30.4%, 26.2%, 14.0%, 8.6%, and 6.4% of the 642 elderly patients surveyed for three years, at the time of registration, respectively. Morbidity and mortality rates of total cerebro-cardiovascular diseases, stroke, and heart diseases, were 27.6 and 7.81/1,000 patient-years, 15.1 and 3.6/1,000 patient-years, 10.4 and 4.2/1,000 patient-years, respectively. These results were similar or even better than those of megatrials of antihypertensive treatments for elderly patients in Europe and United States. After adjustment for potential confounding factors, multiple logistic analysis revealed that a past history of ischemic heart disease, use of the old-type antihypertensive drugs, male gender, and diastolic high blood pressure were independent risk factors for the morbidity of cerebro-cardiovascular diseases taking the group of non-cerebro-cardiovascular disease as the reference group. We also identified 22 cases of newly occurred malignancies including 7 fatal cases. However, none of the antihypertensives was significantly related to the occurrence of malignancies. These results lead support to the tendencies in the use of antihypertensive drugs in Japan.
- Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.Nihon Ronen Igakkai Zasshi.1999 May;36(5):342-52.
- Although calcium-channel blockers and angiotensin-I-converting enzyme inhibitors are often used for treatment of hypertension in the elderly in Japan compared to those in the United States and in European countries, there have been few investigations on the prognosis of the elderly receiving these a
- PMID 10466352
- The anti-tachycardic mechanism of a direct-acting vasodilator, budralazine, in rats.
- Yoshioka M1, Minami M, Saito H.Author information 1First Department of Pharmacology, Hokkaido University School of Medicine, Sapporo, Japan.AbstractThe present study was undertaken to elucidate the anti-tachycardic effect of a direct-acting vasodilator, budralazine, using an electrophysiological technique. Normotensive male Wistar rats were used. Rats were anesthetized intraperitoneally with urethane and alpha-chloralose. Intravenous administration of budralazine (0.5-5.0 mg/kg) produced a dose-dependent reduction of mean arterial pressure in anesthetized rats. At doses of 0.5 and 1.0 mg/kg, budralazine induced bradycardia accompanied with a decrease in cardiac sympathetic nerve activity (ICNA). Preganglionic adrenal sympathetic nerve activity (ASNA) was also reduced by budralazine (1.0 mg/kg). A 0.5 mg/kg of budralazine neither influenced carotid sinus nerve activity nor augmented aortic depressor nerve activity (ADNA). On the contrary, at dose of 5.0 mg/kg, budralazine produced a tachycardia accompanied with increases in both ICNA and ASNA. The ADNA was decreased by budralazine (5.0 mg/kg) significantly. These findings suggest that the central sympathoinhibitory action of budralazine may be responsible for the anti-tachycardic effect of budralazine and baroreceptor-mediated tachycardia occurred after high dose of budralazine.
- Clinical and experimental hypertension. Part A, Theory and practice.Clin Exp Hypertens A.1991;13(5):1107-14.
- The present study was undertaken to elucidate the anti-tachycardic effect of a direct-acting vasodilator, budralazine, using an electrophysiological technique. Normotensive male Wistar rats were used. Rats were anesthetized intraperitoneally with urethane and alpha-chloralose. Intravenous administra
- PMID 1773498
- Effects of antihypertensive drugs on experimental cerebral ischemia in spontaneously hypertensive rats.
- Tanaka S1, Ashida S, Akashi A.Author information 1Research Institute, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.AbstractThe effects of antihypertensive drugs on ischemic cerebral damage were investigated using the bilateral carotid artery occlusion (BCAO) model in SHR. Oral budralazine and nifedipine, at doses that increased cerebral blood flow (CBF) in SHR in our previous study (Tanaka, S. et al., Folia Pharmacol, Japan, 87, 1986), significantly improved cerebral energy failure after the BCAO, but prazosin which does not increase CBF had no effect on the energy failure. These results suggest that the amelioration by these antihypertensive drugs of the energy failure after the BCAO results from its CBF-increasing effects in SHR.
- Japanese journal of pharmacology.Jpn J Pharmacol.1990 Aug;53(4):502-5.
- The effects of antihypertensive drugs on ischemic cerebral damage were investigated using the bilateral carotid artery occlusion (BCAO) model in SHR. Oral budralazine and nifedipine, at doses that increased cerebral blood flow (CBF) in SHR in our previous study (Tanaka, S. et al., Folia Pharmacol, J
- PMID 2214372
Japanese Journal
- 降圧薬療法下通院中の老年者高血圧患者の３年間予後に関する多施設調査 脳心血管疾患および悪性疾患の発症・死亡について:脳心血管疾患および悪性疾患の発症・死亡について
- 荻原 俊男,森本 茂人,中橋 毅,日和田 邦男,松岡 博昭,松本 正幸,島本 和明,大内 尉義,阿部 功,三上 洋,石光 俊彦,小原 克彦, ,高崎 幹裕,増田 敦,宗平 純一,江頭 正人,高川 芳勅,清原 裕,井林 雪郎,中村 敏子,藤島 正敏
- 日本老年医学会雑誌 36(5), 342-352, 1999
- 老年者高血圧例に対する降圧薬治療において, 本邦では欧米に比べCa拮抗薬やACE阻害薬の使用頻度は高いが, 我が国においてこれらの降圧薬による治療例の長期予後については十分に明らかにされていない. 長寿科学総合研究事業「老年者の高血圧治療ガイドライン作成に関する研究」班による共同研究として, 60歳以上の降圧薬治療下の老年者高血圧例700例の3年間にわたる予後追跡調査を実施した. 観察期間中に脱落 …
- NAID 130003652503
- Effects of antihypertensive drugs on experimental cerebral ischemia in spontaneously hypertensive rats.
- , ,
- The Japanese Journal of Pharmacology 53(4), 502-505, 1990
- … Oral budralazine and nifedipine, at doses that increased cerebral blood flow (CBF) in SHR in our previous study (Tanaka, S. …
- NAID 130000832883
- 2) 血管拡張薬Budralazineのラット血圧, 心拍数および交感神経活動におよぼす影響 : 日本循環器学会第56回北海道地方会
- 矢萩 晴久,門関 芳夫,吉岡 充弘,南 勝,斎藤 秀哉
- Japanese circulation journal 53(SupplementI), 1, 1989-04-01
- NAID 110002605762
Related Links
- TRIVENI INTERCHEM PVT. LTD. - Exporter, Manufacturer, Distributor, Supplier, Trading Company of Budralazine based in Vapi, India Select Language English Spanish French German Italian Chinese (Simplified) Japanese Korean ...
- Budralazine is a medicine available in a number of countries worldwide. A list of US medications equivalent to Budralazine is available on the Drugs.com website. ... Important Notice: The Drugs.com international database is in BETA ...
Related Pictures
★リンクテーブル★
| リンク元 | 「ブドララジン」 |
「ブドララジン」
- 英
- budralazine
- 商
- ブテラジン